MSCs engineered to release IL7 and IL12 shift the chronic inflammatory Th2 profile of the tumor microenvironment into a more favorite Th17/Th1 profile with an improved and prolonged anti-tumor CAR T cell response. This evidence concerns the gene IL7 and neoplasm.